Salarius Pharmaceuticals Inc.
13F holders, Q2 2024 (June 30)8holders
$2.38avg. 13F price*
At the end of Q2 2024, 8 institutions reported holding Salarius Pharmaceuticals Inc. in their 13F filings. The largest holders were Armistice Capital, LLC ($54K), Tower Research Capital LLC (TRC) ($8K) and UBS Group AG ($269).
- Company
- Salarius Pharmaceuticals Inc.
- CUSIP
- 79400X404
- Latest filing quarter
- Q3 2025
History
Number of 13F holders
Total Exit/New Position Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 9 | $62K |
| Exits | 0 | $0 |
Ownership 8 holders
| Armistice Capital, LLC | 0.00% | New | 22,750 | $54K |
| Tower Research Capital LLC (TRC) | 0.00% | New | 3,178 | $8K |
| UBS Group AG | 0.00% | New | 113 | $269 |
| Osaic Holdings, Inc. | 0.00% | New | 53 | $126 |
| Morgan Stanley | 0.00% | New | 7 | $17 |
| Bank of America Corp. | 0.00% | New | 6 | $15 |
| Wells Fargo & Company | 0.00% | New | 1 | $2 |
| BlackRock Inc. | 0.00% | New | 1 | $2 |
"% of holder's portfolio" is SALARIUS PHARMACEUTICALS INC's weight in each manager's 13F, not the share of Salarius Pharmaceuticals Inc. the manager owns.